Positive data from Geron liver and lung cancer trials published
8th Sep 2005, 00:52 GMT
Geron has announced the publication of data demonstrating the efficacy of its pan-cancer telomerase inhibitor drug GRN163L in mouse models of human hepatocellular carcinoma and human metastatic lung cancer.
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol